Table 4 Interaction analysis between pSS and anti-osteoporosis drugs users in Case 3.

From: Primary Sjogren syndrome increases the risk of bisphosphonate-related osteonecrosis of the jaw

Group

Event

Incidence Rate

IRR

95 CI for IRR

Adj. HR‡

95 CI for Adj. HR

pSS-BIS

14

2327.95

3.05**

(1.56–5.97)

3.01**

(1.50–6.06)

pSS-NONBIS

4

615.90

0.81

(0.28–2.34)

0.79

(0.29–2.20)

NONpSS-BIS

29

1051.65

1.38

(0.79–2.40)

1.34

(0.77–2.34)

NONpSS-NONBIS (Ref.)

22

762.55

    
  1. (1) *0.01 ≤ p < 0.05, **0.0001 ≤ p < 0.01, ***p < 0.0001. (2) ‡ADJ. HR was adjusted by sex, comorbidities, and age at the initiation of bisphosphonate use.
  2. pSS primary Sjogren syndrome, IRR incidence rate ratio, 95 CI 95% confidence interval, Adj. HR adjusted hazard ratio, pSS-BIS primary Sjogren syndrome with bisphosphonate user, pSS-NONBIS primary Sjogren syndrome with non-bisphosphonate user, NONpSS-BIS non-primary Sjogren syndrome with bisphosphonate user, NONpSS-NONBIS non-primary Sjogren syndrome with non-bisphosphonate user, Ref reference.
Back to article page